G
Gabriel Etienne
Researcher at French Institute of Health and Medical Research
Publications - 179
Citations - 10857
Gabriel Etienne is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 38, co-authored 163 publications receiving 9386 citations. Previous affiliations of Gabriel Etienne include University of Bordeaux & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
Management of Chronic Myelogenous Leukemia Using Therapeutic Drug Monitoring of Imatinib: The French Experience of a Centralized Laboratory
Mathieu Molimard,Stéphane Bouchet,Gabriel Etienne,Laurence Legros,Delphine Rea,Françoise Huguet,Karine Titier,Nicholas Moore,Josy Reiffers,Coralie Belanger,Francois-Xavier Mahon +10 more
TL;DR: Therapeutic drug monitoring of imatinib appears to be helpful for the management of CML patients and the resulting database allows a better understanding and use of this treatment.
Journal ArticleDOI
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
Jim Canet,Pascale Cony-Makhoul,Sébastien Orazio,Edouard Cornet,Xavier Troussard,Marc Maynadié,Gabriel Etienne,Alain Monnereau +7 more
TL;DR: In this paper, the TKI generation effect on achievement of MMR in first-line therapy was assessed through a multivariate competitive risk analysis, and the results were consistent with clinical trials.
Journal ArticleDOI
Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score
Franck E. Nicolini,Philippe Rousselot,Stephane Giraudier,Gabriel Etienne,Hyacinthe Johnson-Ansah,Lydia Roy,Pascale Cony-Makhoul,Yann Guillermin,Mohamad Sobh,Pierre Marie,Driss Kamar,Hesham Mohamed,Denis Caillot,Delphine Rea +13 more
TL;DR: This national study retrospectively and prospectively analysed the predictive value of this score in CP CML resistant or intolerant to IM pts from numbers of academic institutions (university and non-university hospitals).
Journal Article
Nilotinib induces deeper molecular responses vs continued imatinib in patients with ph+ chronic myeloid leukemia (CML) with detectable disease after ≥ 2 years on imatinib: ENESTcmr 12-months results
C. Cervantes,Timothy P. Hughes,Gabriel Etienne,C.A. De Souza,P.E. Dorlhiac Llacer,Anthony P. Schwarer,Brian Leber,Jeffrey H. Lipton,Nelson Spector,John V. Reynolds,LaTonya Collins,Tomasz Szczudlo,Delphine Rea +12 more
Journal ArticleDOI
Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results
Franck E. Nicolini,Gabriel Etienne,Viviane Dubruille,Lydia Roy,Françoise Huguet,Laurence Legros,Stéphane Giraudier,Valérie Coiteux,Agnès Guerci-Bresler,Pascal Lenain,Delphine Rea,Shanti Ame,Pascale Cony-Makhoul,Martine Gardembas,Eric Hermet,Philippe Rousselot,Marie-Claude Gagnieu,Stephane Morisset,Christine Pivot,Madeleine Etienne,François Guilhot,Stéphanie Dulucq,Francois-Xavier Mahon +22 more
TL;DR: The ≥4-year follow-up of newly diagnosed CP-CML patients with nilotinib combined to pegylated interferon-alpha 2a in de novo chronic phase chronic myeloid leukemia patients for toxicity and efficacy is reported.